Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-05-08 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES CHINA NMPA APPROVAL OF CONDUCTING A PHASE IIA CLINICAL TRIAL FOR ASC10 TO TREAT RESPIRATORY SYNCYTIAL VIRUS INFECTION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the approval by the China National Medical Products Administration (NMPA) to conduct a Phase IIa clinical trial for a drug candidate ASC10. It provides details about the clinical trial, preclinical research, and market context. The document is relatively short (4186 characters) and is an announcement of a regulatory approval and business development rather than a financial report or detailed clinical study report. It does not contain financial statements, earnings data, or detailed management discussion. It is not a report publication announcement since it contains substantive information about the clinical trial approval and related business update. The content fits best under a general regulatory or business update announcement category. Given the available filing categories, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities for Ascletis Pharma Inc., specifically focusing on authorized and issued share capital, share options, and other related share movements. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with Exchange Listing Rules under Chapter 19B. The content includes tables of share capital balances, share option schemes, and confirmations related to securities movements. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is regulatory in nature, reporting share capital and share option movements as required by the exchange. This fits the category of a Regulatory Filing (RNS) as it is a compliance report submitted to the exchange and does not constitute a financial report or announcement of a report publication. The document length (5801 characters) and detailed data support this classification with high confidence.
2023-05-05 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 April 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities for an equity issuer listed on the Hong Kong Stock Exchange. It includes information on authorized and issued share capital, share options, and confirmations related to securities issuance. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting on share capital and share movements for the month ended April 30, 2023. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital movements and confirmations, fitting the category of Regulatory Filings (RNS).
2023-05-02 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES ASC40, A FIRST-IN-CLASS, ONCE-DAILY ORAL FASN INHIBITOR, ACHIEVED ENDPOINTS IN PHASE II CLINICAL TRIAL FOR ACNE
Capital/Financing Update Classification · 85% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the successful Phase II clinical trial results of their drug ASC40 for acne treatment. It contains detailed clinical trial data, safety and efficacy results, and future trial plans. There is no indication that this is a full financial report, earnings release, or regulatory filing. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. The document is a business update focused on clinical development progress, which fits best under the category of a Capital/Financing Update (CAP) as it informs shareholders and investors about a significant development that could impact the company's value and future financing or capital strategy. It is not a direct financial report but a material business update related to product development and potential future commercial impact.
2023-05-02 English
FORM OF PROXY FOR ANNUAL GENERAL MEETING (or any adjournment thereof)
AGM Information Classification · 95% confidence The document is a 'Form of Proxy for Annual General Meeting' for World Houseware (Holdings) Limited. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including adoption of audited financial statements, re-election and appointment of directors, re-appointment of auditors, and granting mandates related to shares. The content is procedural and related to the conduct of the AGM rather than the AGM report or presentation itself. This type of document is typically classified as AGM Information (AGM-R) because it is a material shared for the AGM meeting process, not the full Annual Report or other filings.
2023-04-27 English
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled '2022 Annual Report' and contains detailed sections typical of a full annual report, including Corporate Information, Chairman's Statement, Management Discussion and Analysis, Biographical Details of Directors and Senior Management, Corporate Governance Report, Environmental, Social and Governance Report, Directors' Report, Independent Auditor's Report, and full Consolidated Financial Statements with notes. The document covers the full fiscal year ended 31 December 2022 and includes comprehensive financial data and analysis. The length of the document (15,000 characters) and the detailed content confirm it is the full Annual Report, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-04-27 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.